hotspot -WSS

hotspot

author：leisure time 2025-09-30 20:35:13 - browse：621

A new asthma treatment that could be administered just once every six months has succeeded in two Phase 3 trials, developer GlaxoSmithKline announced Tuesday.

The drug, depemokimab, is designed to treat asthma by targeting a protein called interleukin-5, or IL-5. The protein is linked to the type of inflammation found in most severe asthma cases, according to the pharma company.

Depemokimab hit its primary endpoints in the trials, reducing asthma attacks over a year’s time frame. The company didn’t disclose exact details from the SWIFT-1 and SWIFT-2 trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： Readout Newsletter: Medeor's stem cell study, Moderna's stock dip

knowledge

WSS

Brain injuries and the importance of a second opinion

Adam's Biotech Scorecard: PDS Biotech's survival benefit is overstated

Fertility clinic egg and embryo storage is a disaster

All of Us, NIH's precision medicine initiative, gets a big boost

To spot an incipient stroke, tiny brain probe acts ‘like a microscope’

Travis Kelce and the trap of celebrity vaccine endorsements

focus

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

entertainment

Medical records are filled with copy

WuXi Biologics beefs up its lobbying operation

Malaria cases in Florida and Texas: Here’s what you need to know

Free medical tuition alone isn't enough to close gaps in primary care

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Cherokee Nation medical school graduates its first class

Affirmative action in medical school literally saved lives

Galapagos to make CAR

Hollywood unions extend contract negotiations for actors

Bill would allow buprenorphine prescription for addiction via telehealth

entertainment

Cherokee Nation medical school graduates its first class

Life sciences investors close nearly $6 billion in new funds

Free medical tuition alone isn't enough to close gaps in primary care

Inari Medical to buy amputation prevention company LimFlow

Lung cancer screening guidelines updated for cigarette smokers

How to convince healthy people to buy insurance

Wikipedia

hotspot

knowledge

knowledge